VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19

Zhujun Cao(Shanghai Institute of Hematology), Ren Zhao(Shanghai Institute of Hematology), Shuya Mei(University of Chicago), Yueqiu Gao(Shanghai University), Yiqing Shi(Shanghai Institute of Hematology), Hong Bao(Shanghai Jiao Tong University), Yuan Gao(Chinese Academy of Medical Sciences & Peking Union Medical College), Zijia Song(Shanghai Institute of Hematology), Guang Ning(Shanghai Jiao Tong University), Qing Xie(Shanghai Jiao Tong University), Peizhan Chen(National Clinical Research), Yifei Zhang(Shanghai Institute of Hematology), Qin Zhang(Zhejiang Chinese Medical University), Jing Sun(First Affiliated Hospital of Guangzhou Medical University), Weijing Wang(Shanghai Institute of Hematology), Yiping Xu(National Clinical Research), Weiyi Gao(Shanghai Innovative Research Center of Traditional Chinese Medicine), Zhilei Cui(Shanghai Institute of Hematology), Xianmin Meng(Shanghai Public Health Clinical Center), Honglian Gui(Shanghai Institute of Hematology), Haiyan Feng(Shanghai Public Health Clinical Center), Yimei Jiang(Shanghai Institute of Hematology)
New England Journal of Medicine
December 28, 2022
Cited by 227


Related Papers